Linda R Mileshkin

13PUBLICATIONS

112CO-AUTHORS

Haematological tumoursCancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modelling

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jul 08, 2026

Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

|May 20, 2025

Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary.

Richard J Rebello, Atara Posner, Ruining Dong

|Nov 14, 2024

Unravelling mutational signatures with plasma circulating tumour DNA.

Sebastian Hollizeck, Ning Wang, Stephen Q Wong

|Oct 21, 2024

Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis.

Angelina Tjokrowidjaja, Peey-Sei Kok, Yoland C Antill

|Oct 07, 2024

Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.

Dione van Dijk, Lisa Vermij, Alicia León-Castillo

|Jul 20, 2024

Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.

Alexander B Olawaiye, Jae-Weon Kim, Andrea Bagameri

Pageof 3

Frequent Collaborators

Tjalling Bosse

Nanda Horeweg

Richard W Tothill

Christopher Steer

Richard Rebello

Ana Oaknin

Ian M Collins

Anna DeFazio

Clare L Scott

David D L Bowtell

Frequent Collaborators

Tjalling Bosse

Nanda Horeweg

Richard W Tothill

Christopher Steer